Chemoprevention with aromatase inhibitors - Trial strategies

Journal of Steroid Biochemistry and Molecular Biology

Volumn 79, Issue 1-5, 2001, Pages 143-149

  Goss, Paul E ^a   Strasser, Kathrin ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b Wilhelminenspital der Stadt Wien   (Austria)

Author keywords

Aromatase inhibitors; Breast cancer; Chemoprevention

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROSTENEDIONE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

BONE DENSITY; BREAST CARCINOMA; BREAST LESION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ESTRADIOL BLOOD LEVEL; HUMAN; MAMMOGRAPHY; MONOTHERAPY; PRECANCER; QUALITY OF LIFE; RISK ASSESSMENT; TOXICITY;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COHORT STUDIES; ENZYME INHIBITORS; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASMS, HORMONE-DEPENDENT; PILOT PROJECTS; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035716163     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00160-1     Document Type: Conference Paper

References (66)

1. Recent trends in US breast cancer incidence, survival and mortality rates
2. Mechanisms of disease: Estrogen and the risk of breast cancer
3. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer
4. Oestradiol synthesis from C19 steroids by human breast cancers
5. A reassessment of the role of breast tumor aromatization
6. Biological significance of aromatase activity in human breast tumors
7. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
8. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy
9. Edinburgh adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial
10. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent
11. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1
12. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
13. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
14. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor
15. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: Toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone
16. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors
17. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
18. CGS 16949A, a new nonsteroidal aromatase inhibitor: Effects on hormone-dependent and -independent tumors in vivo
19. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors
20. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
21. Aromatase inhibitors - Mechanisms of steroidal inhibitors
22. Aromatase inhibitors - Mechanisms for non-steroidal inhibitors
23. Pharmacology of inhibitors of estrogen biosynthesis
24. Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women: Findings highlight the importance of receptor status assessment prior to treatment initiation
25. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer
26. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer
27. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview and analysis of two phase III clinical trials
28. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma
29. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
30. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
31. A phase III trial comparing vorozole (RIVIZOR™) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer
32. Vorozole (Rivizor™) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen
33. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
34. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
35. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal women - Combined analyses from two identically designed multicenter trials
36. Letrozole is superior to tamoxifen as first-line hormonal treatment of post-menopausal women with locally advanced metastatic breast cancer (bc)
37. Neo-adjuvant treatment of postmenopausal breast cancer patients and impact on breast-conserving surgery: A double-blind radomized study comparing letrozole to tamoxifen - The Letrozole Neo-Adjuvant Breast Cancer Study Group
38. Exemestane (Aromasin) is active and well tolerated in first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): Results of a randomized phase II trial
39. Experimentally induced mammary tumors in rats
40. Animal models of breast cancer: Experimental design and their use in nutrition and psychosocial research
41. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities
42. Aromatase overexpression and breast hyperplasia, an in vivo model - Continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands
43. Biomarkers as intermediate and points in chemoprevention trials
44. Validation of intermediate end points in cancer research
45. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
46. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types
47. Cigarette smoking and breast cancer risk among young women (United States)
48. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer
49. Steroid dynamics in the normal and carcinomatous mammary gland
50. Can mammographic densities predict effects of tamoxifen on the breast?
51. Mammographic patterns as a predictive biomarker of breast cancer risk: Effect of tamoxifen
52. Macronutrient intake and change in mammographic density at menopause: Results from a randomized trial
53. Towards an understanding of breast cancer etiology
54. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study
55. Bone mineral density and risk of breast cancer in older women: The study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group
56. Bone mass and the risk of breast cancer among postmenopausal women
57. A prospective study of endogenous estrogens and breast cancer in postmenopausal women
58. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
59. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: Associations and interactions in an international case-control study
60. Mammographic features and breast cancer risk: Effects with time, age, and meopause status
61. Inherited susceptibility to breast cancer
62. Current perpectives on radiation-induced breast cancer
63. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer
64. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women
65. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk